





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b> <b>C07D 215/56, C07F 5/02</b> <b>// A61K 31/47</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 88/ 07993</b> <b>(43) International Publication Date:</b> 20 October 1988 (20.10.88)
<b>(21) International Application Number:</b> PCT/HU88/00019 <b>(22) International Filing Date:</b> 8 April 1988 (08.04.88) <b>(31) Priority Application Numbers:</b> 1505/87 1505/87 <b>(32) Priority Dates:</b> 8 April 1987 (08.04.87) 26 February 1988 (26.02.88) <b>(33) Priority Country:</b> HU <b>(71) Applicant (for all designated States except US):</b> CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA RT.[HU/HU]; Tó utca 1-5, H-1045 Budapest IV (HU). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> HERMECZ, István [HU/HU]; Molnár u. 53, H-1056 Budapest (HU). KERESZTURI, Géza [HU/HU]; Széna tér 1/b, H-1015 Budapest (HU). VASVÁRI, Lelle [HU/HU]; Goldmark K.u. 33, H-1122 Budapest (HU). HORVÁTH, Ágnes [HU/HU]; Budenz u. 30/a, H-1021 Budapest (HU). BALOGH, Mária [HU/HU];		Barátság u. 20, H-2120 Dunakeszi (HU). RITLI, Péter [HU/HU]; Ó u. 43, H-1066 Budapest (HU). SIPOS, Judit [HU/HU]; Sáfrány u. 10, H-1116 Budapest (HU). PAJOR, Anikó [HU/HU]; Ferenc krt. 36, H-1092 Budapest (HU). MÁRMAROSI, Katalin [HU/HU]; Ybl M. st. 19, Biatorbágy, H-2051 Biatorbágy (HU). <b>(74) Agent:</b> PATENTBUREAU DANUBIA; Bajcsy-Zsilinszky út 16, H-1051 Budapest V (HU). <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US. <b>Published</b> <i>With international search report.</i>	

(54) Title: PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACIDS



**(57) Abstract**

The invention relates to a new process for the preparation of compounds of general formula (I), (wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group) and pharmaceutically acceptable salts thereof which comprises reacting a compound of general formula (II), (wherein R<sup>1</sup> and R<sup>2</sup> stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms and optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms) with a piperazine derivative of general formula (III), (wherein R<sup>3</sup> stands for hydrogen, methyl or ethyl) or a salt thereof and subjecting the compound of general formula (IV) thus obtained, (wherein R, R<sup>1</sup> and R<sup>2</sup> are as stated above) to hydrolysis after or without isolation and if desired converting the compound of general formula (I) thus obtained into a salt thereof or setting free the same from its salt. The compounds of general formula (I) are known antibacterial agents. The advantage of the present invention is that it makes the desired compounds of general formula (I) available in a simple manner, with high yields and in a short reaction time.

***FOR THE PURPOSES OF INFORMATION ONLY***


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

## PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACIDS

This invention relates to a new process for the preparation of 1-cyclopropyl-7-substituted-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid derivatives and pharmaceutically acceptable salts thereof.

It is known that the 1-cyclopropyl-7-substituted-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid derivatives of the general Formula I




/I/

/wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group/ possess high antibacterial activity /Eur. J. Clin. Microbiol. 1983, 2, page 111; J. Clin. Pharmacol. 1985, 25, page 82; Drugs Exptl. Clin. Res. 1985, 5, page 317./


The quinoline carboxylic acids of the general Formula I can be prepared by reacting 1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid and a cyclic amine in the presence of a solvent at a temperature of 135-140 °C for 2 hours /German Off. 3.033.157; German Off. 3.142.854/.

According to the present invention there is provided a new process for the preparation of 1-cyclopropyl-7-substituted-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid derivatives of the general Formula I

5 /wherein R has the same meaning as stated above/ which comprises reacting a compound of the general Formula II




15 /wherein R<sup>1</sup> and R<sup>2</sup> are the same or different and stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms/ with a cyclic amine of the general Formula



/wherein R<sup>3</sup> stands for hydrogen, methyl or ethyl/ or a salt thereof and subjecting the compound of the general

25 Formula IV

- 3 -



/IV/

5

/wherein R, R<sup>1</sup> and R<sup>2</sup> are the same as stated above/ thus obtained to hydrolysis.

The advantage of the process of the present invention is that it makes the desired compound of the general Formula I available in a simple manner with high yields and in a short reaction time.

According to a preferred form of embodiment of the process of the present invention the borate derivative of the general Formula IV /wherein R, R<sup>1</sup> and R<sup>2</sup> are as stated above/ is converted into the desired quinoline-3-carboxylic acid of the general Formula I without isolation.

The borate derivatives of the general Formula IV are new compounds.

The borate derivatives of the general Formula II and the cyclic amine of the general Formula III can be reacted optionally in the presence of an inert organic solvent and an acid binding agent.

As inert organic solvents preferably acid amides /e.g. dimethyl formamide, dimethyl acetamide/, ketones /e.g. acetone, methyl ethyl ketone/, ethers /e.g. dioxane, tetrahydrofuran, diethyl ether/, esters /e.g. ethyl acetate,

methyl acetate, ethyl propionate/, sulfoxides /e.g. dimethyl sulfoxide/, alcohols /e.g. methanol, ethanol, 1-decanol, butanol/ may be used.

As acid binding agent an organic or inorganic base may be used. From the group of organic bases trialkyl amines /e.g. triethyl amine, tributyl amine/, cyclic amines /e.g. pyridine, 1,5-diazabicyclo/5.4.0/undec-5-ene, 1,5-diazabicyclo/4.3.0/non-5-ene, 1,4-diazabicyclo/2.2.2/octane/ can be mentioned, while as inorganic base preferably hydroxides or carbonates of alkali or alkaline earth metals can be applied. Thus as acid binding agent preferably potassium carbonate, potassium hydrogen carbonate, sodium hydroxide, calcium hydroxide, etc. or an excess of the amine of the general Formula III can be used.

The borone derivative of the general Formula II and the cyclic amine of the general Formula III can be reacted at a temperature ranging from 0 to 200 °C, depending on the solvent used. The reaction time may vary between half an hour and 10 hours depending on the reaction temperature. If the reaction is carried out at an elevated temperature, the reaction time can be shortened. The above reaction conditions are but preferable values and other conditions may be used as well.

The borates of the general Formula IV /wherein R, R<sup>1</sup> and R<sup>2</sup> are as stated above/ can be hydrolysed to the desired quinoline-3-carboxylic acids of the general Formula I, after or without isolation, under acidic

or basic conditions. The compound of the general Formula IV /wherein R is as stated above/ precipitates from the reaction mixture e.g. on cooling and can be separated e.g. by filtration or centrifuging, if desired.

5           Basic hydrolysis may preferably be carried out by heating an aqueous solution of hydroxydes or carbonates of alkali metals or hydroxides of alkaline earth metals, One may preferably use an aqueous solution of sodium hydroxide, potassium hydroxide, sodium carbonate, 10   potassium carbonate, calcium hydroxide, potassium hydrogen carbonate. Organic amines /e.g. triethyl amine/ may also be applied in the hydrolysis step.

          Acidic hydrolysis may preferably be accomplished by using an aqueous mineral acid. One may preferably 15   proceed by hydrolysing a borate of the general Formula IV by heating same with an aqueous solution of hydrochloric acid, hydrogen bromide, sulfuric acid or phosphoric acid. Hydrolysis may also be accomplished by using organic acids /e.g. acetic acid, propionic 20   acid, etc/.

          Hydrolysis of the compounds of the general Formula IV may also be carried out in aqueous medium in the presence of a water-miscible organic solvent. For this purpose e.g. alcohols /e.g. methanol, ethanol/, ketones 25   /e.g. acetone/, ethers /e.g. dioxane/, acid amides /e.g. formamide, dimethyl formamide/, sulfoxides /e.g. dimethyl sulfoxide/, or pyridine may be used.

The quinoline-3-carboxylic acid of the general Formula I thus obtained may be isolated e.g. by adjusting the pH value of the aqueous solution to a suitable value and separating the precipitated crystals e.g. by filtration or centrifuging or by liophylization of the aqueous reaction mixture.

The compounds of the general Formula I can be converted into pharmaceutically acceptable salts thereof by methods known per se. Thus preferably acid addition salts formed with hydrogen halides, sulfonic acids, sulfuric acid or organic acids. One may preferably form chlorides, bromides, 4-methyl-phenyl-sulfonates, methane sulfonates, maleates, fumarates, benzoates, etc. The compounds of the general Formula I form salts with alkali or alkaline earth metals or other metal ions as well. Accordingly sodium, potassium, magnesium, silver, copper salts, etc. may be prepared.


The compounds of the general Formula I and pharmaceutically acceptable salts thereof can be converted into hydrates /e.g. hemihydrates, trihydrates, etc./ by methods known per se.

According to a further aspect of the present invention there are provided new compounds of the general Formula IV /wherein  $R$ ,  $R^1$  and  $R^2$  are as stated above/.

The starting materials of the general Formula II can be prepared e.g. by reacting 1-cyclopropyl-6-fluoro-7-chloro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid /German Off. 3.141.854/ with a borone derivative /such



as a compound of the general Formula V



/V/

5 /wherein  $R^1$ ,  $R^2$  and  $R^3$  stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms/ or with fluoroborate in an aqueous or an organic medium.

10 Further details of the present invention are to be found in the following Examples without limiting the scope of protection to the said Examples.

#### Example 1

15 4.1 g of /1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylate- $O^3, O^4$ /-bis/aceto- $O$ /-borone and 2.8 g of piperazine anhydride are heated in 16 ml of dimethyl sulfoxide to 110 °C under stirring. 40 ml of a 3 % w/v aqueous sodium hydroxide solution are  
20 added to the brownish-red solution and the reaction mixture is boiled under reflux for an hour. The hot pale-yellow solution is filtered and the pH value is adjusted to 7 by adding 1.8 ml of 96 % acetic acid. The reaction mixture is cooled to room temperature, the precipitated  
25 white crystals are filtered, washed with water and methanol and dried. The crude product is purified by boiling in 10 ml water. Thus 2.99 g of 1-cyclopropyl-6-fluoro-7-/1-piperazinyl/-1,4-dihydro-4-oxo-quinoline-3-carboxylic

acid are obtained. The product decomposes at 255 °C.

Analysis for the Formula  $C_{17}H_{18}FN_3O_3$ :

Calculated: C=61.62 % H=5.48 % N=12.68 %

Found: C=61.58 % H=5.50 % N=12.61 %.

5

### Example 2

By reacting /1-cyclopropyl-6-fluoro-4-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylate- $O^3, O^4$ /-bis/acetato- $O$ /-borone and N-methyl-piperazine according to Example 1.

10 1-cyclopropyl-6-fluoro-7-/4-methyl-piperazino/-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid is prepared. The product decomposes at 248-250 °C.

### Example 3

15 4.1 g of /1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylate- $O^3, O^4$ /-bis/acetato- $O$ /-borone and 3.7 g of N-ethyl-piperazine are heated in 16 ml of dimethyl sulfoxide to 90 °C under stirring. After 10 minutes 40 ml of a 3 % w/w aqueous sodium hydroxide  
20 solution are added and the reaction mixture is boiled for an hour under reflux. The hot solution is filtered and the pH value is adjusted to 7 with 96 % acetic acid. The reaction mixture is cooled, the precipitated crystals are filtered and washed with water. Thus 3.3 g of 1-cyclo-  
25 propyl-7-/4-ethyl-piperazinyl/-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid are obtained. M.p.: 183-185 °C.

Analysis for the Formula  $C_{19}H_{22}FN_3O_3$ :

Calculated: C=63.35 H=6.17 N=11.69


Found: C=63.31 H=6.21 N=11.70

5 Example 4

3.3 g of /1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylate- $O^3, O^4$ /-difluoro-borone are reacted with 3.7 g of N-ethyl-piperazine according to Example 3. Thus 3.4 g of 1-cyclopropyl-7-/4-ethyl-1-  
10 piperaziny1/-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid are obtained which in admixture at any ratio with the product of Example 3 no depression of the melting point occurs.


WHAT WE CLAIM IS:

1. Process for the preparation of compounds of the general Formula I




/I/

/wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group/ and pharmaceutically acceptable salts thereof which comprises reacting a compound of the general Formula II




/II/

/wherein R<sup>1</sup> and R<sup>2</sup> stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms/ with a piperazine derivative of the general Formula III



/III/

/wherein R<sup>3</sup> stands for hydrogen, methyl or ethyl/ or a  
5 salt thereof and subjecting the compound of the general  
Formula IV



/IV/

10 thus obtained /wherein R, R<sup>1</sup> and R<sup>2</sup> are as stated above/  
15 to hydrolysis after or without isolation and if desired  
converting the compound of the general Formula I thus  
obtained into a salt thereof or setting free the acid  
from its salt.

20 2. Process according to Claim 1 which comprises  
reacting a compound of the general Formula II with a  
piperazine derivative of the general Formula III in the  
presence of an organic solvent, preferably an acid amide,  
sulfoxide, ketone, alcohol, ether or ester.

- 12 -

3. Process according to Claim 2 which comprises using dimethyl sulfoxide as organic solvent.

5 4. Process according to Claim 1 which comprises carrying out the reaction of the compounds of the general Formulae II and III in the presence of an acid binding agent.

10 5. Process according to Claim 4 which comprises using an amine or an excess of the compound of the general Formula III as acid binding agent.

15 6. Process according to Claim 1 which comprises carrying out the hydrolysis in acidic medium.

7. Process according to Claim 6 which comprises carrying out the reaction by using as acid an organic or inorganic acid, preferably hydrochloric acid, sulfuric acid or acetic acid.


20

8. Process according to Claim 1 which comprises carrying out the hydrolysis in a basic medium.

25 9. Process according to Claim 8 which comprises using as a base an alkali metal hydroxide, an alkaline earth metal hydroxide or an organic base, preferably an aqueous triethyl amine solution.

## 10. Compounds of the general Formula IV

5






/IV/

- 10 /wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group,  $R^1$  and  $R^2$  stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms/.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/HU 88/00019

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>4</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 07 D 215/56; C 07 F 5/02 // A 61 K 31/47														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">Int.Cl.<sup>4</sup></td> <td style="padding: 5px;">C 07 D 215/56; C 07 F 5/02, 5/04.</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	Int.Cl. <sup>4</sup>	C 07 D 215/56; C 07 F 5/02, 5/04.								
Classification System	Classification Symbols													
Int.Cl. <sup>4</sup>	C 07 D 215/56; C 07 F 5/02, 5/04.													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>9</sup></th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Chemical Abstracts, vol. 103, no. 15, issued 1985, October 14 (Columbus, Ohio, USA), Daiichi Seiyaku "Oxazines" see page 730, column 1, abstract-no. 123 491p &amp; JP, A, 60-78 986 (DAIICHI SEIYAKU) 04 May 1985.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1,3,8)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Chemical Abstracts, vol. 102, no. 7, issued 1985, February 18 (Columbus, Ohio, USA), Daiichi Seiyaku "1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-quinoline-3-carboxylic acids" see page 605, column 1, abstract-no. 62 272y &amp; JP, A, 59-122 470 (DAIICHI SEIYAKU) 14 July 1984.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1,3,8)</td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 10px;">-----</td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	Chemical Abstracts, vol. 103, no. 15, issued 1985, October 14 (Columbus, Ohio, USA), Daiichi Seiyaku "Oxazines" see page 730, column 1, abstract-no. 123 491p & JP, A, 60-78 986 (DAIICHI SEIYAKU) 04 May 1985.	(1,3,8)	Y	Chemical Abstracts, vol. 102, no. 7, issued 1985, February 18 (Columbus, Ohio, USA), Daiichi Seiyaku "1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-quinoline-3-carboxylic acids" see page 605, column 1, abstract-no. 62 272y & JP, A, 59-122 470 (DAIICHI SEIYAKU) 14 July 1984.	(1,3,8)	-----		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
Y	Chemical Abstracts, vol. 103, no. 15, issued 1985, October 14 (Columbus, Ohio, USA), Daiichi Seiyaku "Oxazines" see page 730, column 1, abstract-no. 123 491p & JP, A, 60-78 986 (DAIICHI SEIYAKU) 04 May 1985.	(1,3,8)												
Y	Chemical Abstracts, vol. 102, no. 7, issued 1985, February 18 (Columbus, Ohio, USA), Daiichi Seiyaku "1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-quinoline-3-carboxylic acids" see page 605, column 1, abstract-no. 62 272y & JP, A, 59-122 470 (DAIICHI SEIYAKU) 14 July 1984.	(1,3,8)												
-----														
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="padding: 5px;">27 June 1988 (27.06.88)</td> <td style="padding: 5px;">01 July 1988 (01.07.88)</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px;">AUSTRIAN PATENT OFFICE</td> <td style="padding: 5px; text-align: center;">  </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	27 June 1988 (27.06.88)	01 July 1988 (01.07.88)	International Searching Authority	Signature of Authorized Officer	AUSTRIAN PATENT OFFICE					
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
27 June 1988 (27.06.88)	01 July 1988 (01.07.88)													
International Searching Authority	Signature of Authorized Officer													
AUSTRIAN PATENT OFFICE														



Anhang zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

Annex to the International Search Report on International Patent Application No. PCT/HU 88/00019

Annexe au rapport de recherche internationale relatif à la demande de brevet international n°.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned International search report. The Austrian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche internationale visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office autrichien des brevets.

Im Recherchenbericht angeführtes Patent- dokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
--	--	---	--

JP-A2-60-078 986

04/05/1985

None

JP-A2-59-122 470

14/07/1984

None